Table of Contents Table of Contents
Previous Page  40 / 154 Next Page
Show Menu
Previous Page 40 / 154 Next Page
Page Background



Frail patients need effective tailored treatments to better

control the disease while minimizing the risk of toxicity and

treatment discontinuation. The selection of therapy should

be based on the risk of toxicity and the capacity of patients

to tolerate treatment. Lenalidomide and bortezomib have

an essential role in the treatment of frail patients. Two-drug

regimens including low-dose steroid in combination with

lenalidomide or bortezomib should be considered in this


Disclosure of interest:

Honoraria from Celgene, Janssen-

Cilag, BMS




Trine Lembrecht Jørgensen

Odense University Hospital, Oncology, Odense, Denmark

In January 2014, the Academy of Geriatric Cancer Research

(AgeCare) was launched, thanks to former MASCC president

Professor Jørn Herrstedt. Driven by the fact that in Denmark,

there is no national strategy for the management of elderly

cancer patients, he gathered a research group and applied

among seven other groups to be the 4th elite research center

in Odense University Hospital – and was selected.

The 5-year research plan consists of seven work packages

including epidemiology, biomarkers, surgery, radiotherapy,

and medical cancer treatment. Further, two work packages

focus on supportive care. One of these (WP 6) focuses

specifically on comorbidity and geriatric assessment and

the pre-therapeutic evaluation and optimization. The other

(WP7) focuses on cancer disease-related complications and

treatment-induced adverse effects. Rehabilitation will be

another focus area.

AgeCare consists of 70 national and international

researchers from different cancer-related disciplines.

The international researchers include a number of well-

established SIOG members.

AgeCare plans to initiate 17 PhD courses (3-year positions)

and 10 post doc courses (3-year 50% positions) over the period

of 2014 to 2018. As of September 2016, 8 PhD courses and 5

post doc positions have been initiated. So far, the AgeCare

Group has published 30 articles in peer-reviewed scientific

journals including several on supportive care [1,2] and cancer

epidemiology [3]. The website


an overview of initiated studies, published papers and

researchers. AgeCare welcome interested new researchers to

join one or more projects.


[1] Brygger L &Herrstedt J on behalf of theAcademy of Geriatric

Cancer Research (AgeCare). 5-Hydroxytryptamine3 recep-

tor antagonists and cardiac side effects. Expert Opin Drug

Safe. 2014;13:1407-22.

[2] Winther SB, Jørgensen TL, Pfeiffer P, Qvortrup Q on behalf

of the Academy of Geriatric Cancer Research (AgeCare).

Can we predict toxicity and efficacy in older patients

with cancer? Older patients with colorectal cancer as

an example. ESMO Open 2016;1:e000021. doi:10.1136/


[3] Ewertz M, Christensen K, Engholm G, Kejs AMT, Lund L,

Matzen LE et al. on behalf of the Academy of Geriatric

Cancer Research (AgeCare). Trends in cancer in the elderly

population in Denmark, 1980–2012. Acta Oncol. 2016;55

Suppl 1:1-6

Disclosure of interest:

None declared


Demetris Papamichael

The speaker abstract has not been received at the time of




Laura Lozza

Fondazione IRCCS Istituto Nazionale Tumori, Radiation Oncology 1,

Milano, Italy

Radiotherapy plays an important role in the care of patients

with cancer and forms part of the management of 40% of

patients cured of their disease. Advances have been made

in the past two decades, as improvements in engineering

and computing have enabled technologies such as intensity

modulated radiotherapy (IMRT), image guided radiotherapy

(IGRT), and stereotactic radiotherapy (SRT) to be used in

routine clinical practice

New options of radiation techniques allow the reduction of

possible side effects and toxicity to healthy tissues, providing

more efficient treatments in terms of radiation dose to the

target and areas at risk.

Intensity modulated radiotherapy (IMRT):

IMRT can create

concave treatment shapes and steep dose gradients. This

maximises the sparing of normal tissues, particularly if the

tumour is wrapped around normal structures such as the

spinal cord.

IMRT is particularly useful for head and neck cancers

because of the high number of important normal tissue

structures within close proximity to the tumour.

Benefits have been found in the treatment of many other

treatment sites, including reduced rectal toxicity in patients

with prostate cancer.

For the elderly patients the benefit of this technique comes

from lower intolerance risks along the course of radiation

because of the lower incidence of acute side effects and,

consequently, allowing doses scaling, thus increasing the

probability of tumor control.

Image guided radiotherapy (IGRT):

All radiotherapy is

delivered with imaging at the beginning and intermittently

throughout treatment to ensure accuracy. IGRT uses imaging